DOCSLIB.ORG

DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment. Despite the emergence of this promising technology to capture quantitative information on articular cartilage quality, cationic CECT has not been ii thoroughly investigated in equine tissues in vitro or in vivo, nor has it been investigated in in vivo in any large animal or human subjects. This compilation of studies was designed to critically examine the capacity of cationic CECT to provide quantitative information on articular cartilage quality across a continuum of disease states in horses while dually serving as a translational model to showcase its potential application in humans. The first experiments successfully characterized the diffusion properties of CA4+ into equine articular cartilage in vitro and in vivo, and also established the femoropatellar joint as the optimum joint for use in the subsequent in vivo experimental models. These initial studies also established preliminary evidence of the safety of CA4+ on articular tissues. The experimental in vivo equine impact model delivered a contusive force to articular cartilage that successfully instituted degeneration of the extracellular matrix components and decreased tissue stiffness. This subtle degradation was discernable from healthy articular cartilage using cationic CECT imaging (microCT). In vivo, the clinical cationic CECT attenuation demonstrated fair correlations with the biochemical, mechanical and histologic staining measures, though there was not sufficient delineation among groups to detect significant differences between disease states. Further investigations are warranted to determine how focal sites of injury can be identified from the resolution limited by current CT technology. The second in vivo experimental study generated reparative and degenerative articular cartilage to provide comparisons with healthy tissue. The cationic CECT method, using microCT and clinical scanners, demonstrated an ability to distinguish between these groups of varying iii articular cartilage quality. Though the results were promising, this study revealed the complexity of detecting subtle articular cartilage injury in a solitary imaging examination owing to the inherent biochemical and biomechanical variation that exists across articular surfaces. However, this study confirmed the successful monitoring of articular cartilage through longitudinal examinations. Overall, this collection of studies established that cationic CECT imaging in vitro and in vivo is capable of distinguishing articular cartilage across a spectrum of disease states exemplifying its utility in the comprehensive evaluation of equine articular cartilage. Further work of how this technique compares to other quantitative diagnostic imaging techniques and optimization strategies for routine use are required. Nonetheless, the results of this work reveal the excellent potential of cationic CECT imaging to be incorporated into research and clinical investigations in horses and highlight the feasible translation of this work into human tissues. iv ACKNOWLEDGEMENTS There are many individuals who have been essential in allowing me to complete this work. First and foremost, I acknowledge my graduate committee especially Drs. Chris Kawcak and Laurie Goodrich for serving as my advisors and permitting me to chase my research and clinical interests in orthopedic surgery and articular cartilage imaging. Their immeasurable efforts in providing me with the opportunities and skills necessary to accomplish this work and for my professional development as a clinician scientist are greatly appreciated. I would also like to thank Dr. C Wayne McIlwraith for his valuable advice regarding the in vivo models and in his overall guidance throughout this graduate work and in supporting my long-term career goals. I thank Dr. Myra Barrett, who was very encouraging and generously welcomed a surgeon into her diagnostic imaging domain. A special thanks to Dr. Mark Grinstaff whose cationic contrast agent provided the cornerstone of this work, and who helped diversify my research training experience by letting me join his laboratory in Boston. A very special thanks to Jen (Suddreth) Daniels and the entire Equine Orthopaedic Research Center staff for their care of the research horses and in providing support for the countless early mornings that were required for the in vivo studies. I would also like to thank the Equine Orthopaedic Research Center laboratory personnel: specifically Nikki Phillips for her guidance and assistance with laboratory assays and troubleshooting histology staining protocols and Dr. John Kisiday for his guidance with the hydroxyproline assay. I also would like to thank Jeff Stewart, Anthony Nguyen and Chris Schmit, the diagnostic imaging technologists who assisted with the clinical CT and MR imaging. v I am incredibly grateful for my colleagues and mentors in Boston directed by Dr. Mark Grinstaff whose assistance and encouragement substantially improved the caliber of this work. Dr. Janne T.A. Mäkelä, Dr. Rachel Stewart, Taylor Lawson, Dr. Benjy Cooper and Dr. Brian Snyder all welcomed me into their laboratory space at Boston University and the Beth Israel Deaconess Medical Center broadening my knowledge of cartilage biomechanics, imaging analysis and chemistry while providing the equipment necessary to accomplish the goals of this work. A particular thanks to Drs. Amit Patwa and Jon Freedman who literally synthesized gallons of CA4+ for use in these experiments. I would also like to thank Dr. Valerie Moorman for performing lameness examinations and for her continued guidance, friendship and encouragement throughout my graduate training. I also acknowledge Dr. Katie Seabaugh for performing lameness examinations and for her general support. I thank Dr. Ali Daniel for his friendship, inspiration and discussions about clinical cases and for reinforcing my interest in clinical practice, and Dr. Holly Stewart for her never-ending optimism and reassurance during these last couple of years. I also extend a special thanks to my parents and brother, Judy, Rod and Tim Nelson for their continued support throughout my veterinary and post-graduate training and for their encouragement as I pursue my career goals. vi TABLE OF CONTENTS ABSTRACT .................................................................................................................................... ii ACKNOWLEDGEMENTS .............................................................................................................v CHAPTER 1: THE ROLE OF ADVANCED DIAGNOSTIC IMAGING IN ARTICULAR CARTILAGE EVALUATION ........................................................................................................1 Introduction ..........................................................................................................................1 Pathophysiology of articular cartilage injury ...........................................................2 Diagnostic imaging of articular cartilage .................................................................8 Magnetic resonance imaging .................................................................................10 Compositional assessment .........................................................................13 Contrast-enhanced computed tomography ............................................................16 Contrast media composition ......................................................................17 Contrast media used in computed tomography ..........................................19 Purpose of study .................................................................................................................23
Load more

Recommended publications
  • Not for Immediate Release
    Press Contact: David Pitts Argot Partners 212.600.1902 [email protected] Bracco Imaging Continues its Investment in Delivering Radiological Solutions Growing Breadth of Portfolio, Research, Education and Innovation Initiatives Highlighted at the 2011 RSNA CHICAGO, November 27, 2011 – Bracco Imaging S.p.A. – one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group – is highlighting the Company’s investment and commitment to imaging agents and radiology solutions across modalities through its growing product portfolio, as well as research, education and innovation, at the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which is being held November 27 - December 2, 2011 at Chicago’s McCormick Place, booth #4839. "Bracco remains committed to the diagnostic imaging sector, investing in imaging across modalities, including X-ray, Computed Tomography (CT), Cath Lab, Magnetic Resonance Imaging (MRI), Nuclear Medicine and Ultrasound," according to Fulvio Renoldi Bracco, head of Bracco Imaging, S.p.A. "In a difficult economic climate, where investing in the future is not top of mind, Bracco remains at the forefront. We believe that imaging agents and integrated imaging solutions are critical to support radiologists and other imaging specialists in making an effective diagnosis. Our commitment to providing the market with industry-leading products and solutions, and our partnership with the medical community, therefore remains unchanged." Fulvio Renoldi Bracco concluded: "We perceive this period in the industry, and indeed in the broader markets, as an opportunity to invest and to continue to deliver the best contrast imaging solutions to market.
    [Show full text]
  • Disease Staging Software™ Reference Guide
    Disease Staging Software™ Version 5.26 Reference Guide COPYRIGHT © 1999-2009 THOMSON REUTERS. ALL RIGHTS RESERVED. - 1 - Copyright © 1999-2009 Thomson Reuters. ALL RIGHTS RESERVED. MEDSTAT® Reg. U.S. Pat. & Tm. Off. All rights reserved. No part of this publication may be reproduced, translated or transmitted in any form, by photocopy, microfilm, xerography, recording or any other means, or stored or incorporated into any information retrieval system, electronic or mechanical, without the prior written permission of the copyright owner. Requests for permission to copy any part of this publication or for additional copies should be addressed to: Thomson Reuters 777 E. Eisenhower Pkwy. Ann Arbor, Michigan 48108. The software, data and other information to which this manual relates have been provided under the terms of a License Agreement with Thomson Reuters, Inc. All Thomson Reuters clients using Medstat Disease Staging Software® are required to obtain their own licenses for use of all applicable medical coding schemes including but not limited to: Major Diagnostic Categories (MDCs), Diagnosis Related Groups (DRGs), and ICD-9-CM. Trademarks: Medstat and Medstat Disease Staging Software are registered trademarks of Thomson Reuters, Inc. Intel and Pentium are registered trademarks of Intel Corporation. Microsoft, Windows, Windows NT, Windows 2000, and Windows XP are registered trademarks of Microsoft Corporation. SAS is a registered trademark of the SAS Institute, Inc. AIX and IBM are registered trademarks of the IBM Corporation. Sun and Solaris are trademarks or registered trademarks of Sun Microsystems, Inc. HP-UX is a registered trademark of the Hewlett-Packard Company. Linux® is the registered trademark of Linus Torvalds in the U.S.
    [Show full text]
  • Synovial Fluidfluid 11
    LWBK461-c11_p253-262.qxd 11/18/09 6:04 PM Page 253 Aptara Inc CHAPTER SynovialSynovial FluidFluid 11 Key Terms ANTINUCLEAR ANTIBODY ARTHROCENTESIS BULGE TEST CRYSTAL-INDUCED ARTHRITIS GROUND PEPPER HYALURONATE MUCIN OCHRONOTIC SHARDS RHEUMATOID ARTHRITIS (RA) RHEUMATOID FACTOR (RF) RICE BODIES ROPE’S TEST SEPTIC ARTHRITIS Learning Objectives SYNOVIAL SYSTEMIC LUPUS ERYTHEMATOSUS 1. Define synovial. VISCOSITY 2. Describe the formation and function of synovial fluid. 3. Explain the collection and handling of synovial fluid. 4. Describe the appearance of normal and abnormal synovial fluids. 5. Correlate the appearance of synovial fluid with possible cause. 6. Interpret laboratory tests on synovial fluid. 7. Suggest further testing for synovial fluid, based on preliminary results. 8. List the four classes or categories of joint disease. 9. Correlate synovial fluid analyses with their representative disease classification. 253 LWBK461-c11_p253-262.qxd 11/18/09 6:04 PM Page 254 Aptara Inc 254 Graff’s Textbook of Routine Urinalysis and Body Fluids oint fluid is called synovial fluid because of its resem- blance to egg white. It is a viscous, mucinous substance Jthat lubricates most joints. Analysis of synovial fluid is important in the diagnosis of joint disease. Aspiration of joint fluid is indicated for any patient with a joint effusion or inflamed joints. Aspiration of asymptomatic joints is beneficial for patients with gout and pseudogout as these fluids may still contain crystals.1 Evaluation of physical, chemical, and microscopic characteristics of synovial fluid comprise routine analysis. This chapter includes an overview of the composition and function of synovial fluid, and laboratory procedures and their interpretations.
    [Show full text]
  • Learn the Terms
    Learn the Terms Healthcare is replete with poly-syllabic clinical terminology and unfamiliar acronyms. Learn the Terms is a quick guide for non- clinical personnel to what these terms mean. You can reference these terms below and others in the AHIA Electronic Audit Library – Terms and Acronyms section. Thanks to Theresa Crothers, RN, CMAS for her contribution. Theresa is a nurse auditor for United Audit Systems, Inc., and is 2005 President, American Association of Medical Audit Specialists. Endoscopic Radiologic (continued) EGD: Esophagogastroduodenoscopy is a test that allows the BE: Barium Enema, also known as a Lower GI, examines the lining of the esophagus, stomach, and upper duodenum to be lower intestine a� er the installation of Barium. visualized by the use of a fl exible fi ber-optic or video endoscope. This test is done to diagnose infl ammation, tumors, ulcers, and KUB: Kidney-Ureter-Bladder is an x-ray that shows the organs any other injury to the esophagus and duodenum. Conscious related to the kidney. Each kidney has a ureter that connects to Sedation is used. the bladder. ERCP: Endoscopic Retrograde Cholangio-Pancreatography Fluoroscopy: A continuous beam of x-ray to follow movement allows for the visualization of the pancreas, liver, and gallbladder, in the body. by using a fl exible lighted scope. A contrast medium is injected IVP: Intravenous Pylogram is an x-ray that shows the structures prior to the exam. Conscious Sedation is used. of the urinary tract using an IV contrast. It is done to evaluate Radiologic size and location of kidney stones, cause of urinary tract infections, and tumor diagnosis.
    [Show full text]
  • Validation of a Clinical Prediction Rule for the Differentiation Between Septic Arthritis and Transient Synovitis of the Hip in Children by MININDER S
    COPYRIGHT © 2004 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED Validation of a Clinical Prediction Rule for the Differentiation Between Septic Arthritis and Transient Synovitis of the Hip in Children BY MININDER S. KOCHER, MD, MPH, RAHUL MANDIGA, BS, DAVID ZURAKOWSKI, PHD, CAROL BARNEWOLT, MD, AND JAMES R. KASSER, MD Investigation performed at the Departments of Orthopaedic Surgery, Biostatistics, and Radiology, Children’s Hospital, Boston, Massachusetts Background: The differentiation between septic arthritis and transient synovitis of the hip in children can be difficult. The purpose of the present study was to validate a previously published clinical prediction rule for this differentiation in a new patient population. Methods: We prospectively studied children who presented to a major children’s hospital between 1997 and 2002 with an acutely irritable hip. As in the previous study, diagnoses of septic arthritis (fifty-one patients) and transient synovitis (103 patients) were operationally defined on the basis of the white blood-cell count in the joint fluid, the re- sults of cultures of joint fluid and blood, and the clinical course. Univariate analysis and multiple logistic regression were used to compare the two groups. The predicted probability of septic arthritis of the hip from the prediction rule was compared with actual distributions in the current patient population. The area under the receiver operating char- acteristic curve was determined. Results: The same four independent predictors of septic arthritis of the hip (a history of fever, non-weight-bearing, an erythrocyte sedimentation rate of 40 mm/hr, and a serum white blood-cell count of >12,000 cells/mm3 (>12.0 × 109/L)) were identified in the current patient population.
    [Show full text]
  • Patient Prep Instructions
    SCHEDULING CENTER PHONE: (650) 723-6855 FAX: (650) 723-6036 ● HOSPITAL – 300 Pasteur Drive ● BLAKE WILBUR OUTPATIENT CLINIC – 900 Blake Wilbur Drive ● ADVANCE D MEDICINE CENTER/CANCER CENTER – 875 Blake Wilbur Drive ● STANFORD MEDICINE IMAGING CENTER – 451 Sherman Avenue, Palo Alto ● STANFORD MEDICINE OUTPATIENT CENTER – 450 Broadway, Redwood City PATIENT PREP INSTRUCTIONS PLEASE REGISTER 30 MINUTES PRIOR TO THE APPOINTMENT TIME Prior insurance authorization may be required by your insurance company for this radiology study. Please confirm that you have insurance approval. Please bring any insurance information (card & authorization) and the exam requisition with you to the appointment. Stanford Medicine Imaging Center: Monday-Friday 7:00am to 10:00pm Stanford Medicine Outpatient Center: Monday-Friday 7:00am to 10:00pm Blake Wilbur Outpatient Clinic Registration: Monday-Friday 7:00am to 9:30pm Saturday-Sunday 7:00am to 3:30pm AMC/Cancer Center Registration (1st floor Room CC 1227): Monday-Friday 7:00am to 5:00pm Hospital MRI Registration (Ground Floor): Monday-Friday 7:00am to 9:30pm Saturday-Sunday 7:00am to 2:30pm Nuclear Medicine & PET/CT Registration (2nd Floor H2200): Monday-Friday 7:00am to 5:00pm Hospital Radiology East Registration (1st Floor): Monday-Friday 6:45am to 6:00pm Hospital Registration (Main Admitting): Monday-Friday 5:30am to 9:30pm Saturday-Sunday 7:00am to 9:30pm DIABETIC PATIENTS: If you are a diabetic patient taking any medication that contains Metformin (Glucophage, Glucovance, Metaglip, Actoplus, Prandimet, Kombiglyze, Janumet, Avandamet, Fortamet, and Riomet) and are scheduled for an examination that requires IV contrast (CT, IVP or Arthrogram) DO NOT take your medication on the day of the exam and for 48 hours after.
    [Show full text]
  • ICD~10~PCS Complete Code Set Procedural Coding System Sample
    ICD~10~PCS Complete Code Set Procedural Coding System Sample Table.of.Contents Preface....................................................................................00 Mouth and Throat ............................................................................. 00 Introducton...........................................................................00 Gastrointestinal System .................................................................. 00 Hepatobiliary System and Pancreas ........................................... 00 What is ICD-10-PCS? ........................................................................ 00 Endocrine System ............................................................................. 00 ICD-10-PCS Code Structure ........................................................... 00 Skin and Breast .................................................................................. 00 ICD-10-PCS Design ........................................................................... 00 Subcutaneous Tissue and Fascia ................................................. 00 ICD-10-PCS Additional Characteristics ...................................... 00 Muscles ................................................................................................. 00 ICD-10-PCS Applications ................................................................ 00 Tendons ................................................................................................ 00 Understandng.Root.Operatons..........................................00
    [Show full text]
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
    [Show full text]
  • CPT® Procedural Coding 110 L with Areportoftheprocedure
    20610-20611 2017 Illustrated Coding and Billing Expert for Orthopedics Lower 20610-20611 ICD-9-CM Diagnostic Codes M16.7 Other unilateral secondary 711.05 Pyogenic arthritis involving pelvic osteoarthritis of hip 20610 Arthrocentesis, aspiration and/or region and thigh M17.0 Bilateral primary osteoarthritis of injection, major joint or bursa (eg, 711.06 Pyogenic arthritis involving lower leg knee shoulder, hip, knee, subacromial 713.5 Arthropathy associated with ⇄ M17.11 Unilateral primary osteoarthritis, right bursa); without ultrasound guidance neurological disorders knee 20611 Arthrocentesis, aspiration and/or 714.0 Rheumatoid arthritis ⇄ M17.12 Unilateral primary osteoarthritis, left knee injection, major joint or bursa (eg, 715.15 Osteoarthrosis, localized, primary, pelvic region and thigh M17.2 Bilateral post-traumatic osteoarthritis shoulder, hip, knee, subacromial 715.16 Osteoarthrosis, localized, primary, of knee bursa); with ultrasound guidance, with lower leg M17.5 Other unilateral secondary permanent recording and reporting 715.25 Osteoarthrosis, localized, secondary, osteoarthritis of knee (Do not report 20610, 20611 in pelvic region and thigh ⇄ M1A.051 Idiopathic chronic gout, right hip conjunction with 27370, 76942) 715.26 Osteoarthrosis, localized, secondary, ⇄ M1A.062 Idiopathic chronic gout, left knee (If fluoroscopic, CT, or MRI guidance is lower leg ⇄ M25.052 Hemarthrosis, left hip ⇄ M25.061 Hemarthrosis, right knee performed, see 77002, 77012, 77021) 715.35 Osteoarthrosis, localized, not specified whether primary
    [Show full text]
  • Imaging Services Order Guide Medicare Guidelines Require Explicit Written and Signed Provider Orders
    Imaging Services 2021 Imaging Services Order Guide Medicare guidelines require explicit written and signed provider orders. This guide was created to assist you in ordering and authorizing exams accurately. Please obtain insurance authorizations before scheduling imaging studies. Call one of our licensed/certified technologists if you have questions or comments. NOTE: Please DO NOT call the department to schedule an appointment. CENTRALIZED SCHEDULING . 509-248-9592 GENERAL X-RAY . 509-895-0509 COMPUTED TOMOGRAPHY (CT) . 509-895-0507 MAGNETIC RESONANCE IMAGING (MRI) . 509-895-0505 NUCLEAR MEDICINE . 509-575-8099 `OHANA MAMMOGRAPHY . 509-574-3863 ULTRASOUND . 509-249-5154 VASCULAR ULTRASOUND–Memorial Heart & Vascular . 509-574-0243 VASCULAR STAT REFERRALS–Memorial Heart & Vascular . .509-494-0551 CARDIOVASCULAR SERVICES–Memorial Heart & Vascular . 509-574-0243 BONE DENSITY–Lakeview Campus . 509-972-1170 PROVIDER EMERGENCY . 509-248-7380 Option 0 Consultation of a Clinical Decision Support Mechanism is required to determine if advanced diagnostic imaging services (CT, MRI, Nuclear Medicine, PET) adheres to Appropriate Use Criteria. Order must include Decision Support Number (DSN), G-Code, and Modifier. PHONE | 509-895-0507 PHONE | 509-895-0507 2 3 CT/CAT Scan/Computed Tomography FAX | 509-576-6982 CT/CAT Scan/Computed Tomography FAX | 509-576-6982 *If patient is over 400 lbs., please call the CT department at 509-895-0507. *If patient is over 400 lbs., please call the CT department at 509-895-0507. Consultation of a Clinical Decision Support Mechanism is required. Order must include DSN, G-Code, and Modifier. Consultation of a Clinical Decision Support Mechanism is required. Order must include DSN, G-Code, and Modifier.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Knee Joint Surgery: Open Synovectomy
    Musculoskeletal Surgical Services: Open Surgical Procedures; Knee Joint Surgery: Open Synovectomy POLICY INITIATED: 06/30/2019 MOST RECENT REVIEW: 06/30/2019 POLICY # HH-5588 Overview Statement The purpose of these clinical guidelines is to assist healthcare professionals in selecting the medical service that may be appropriate and supported by evidence to improve patient outcomes. These clinical guidelines neither preempt clinical judgment of trained professionals nor advise anyone on how to practice medicine. The healthcare professionals are responsible for all clinical decisions based on their assessment. These clinical guidelines do not provide authorization, certification, explanation of benefits, or guarantee of payment, nor do they substitute for, or constitute, medical advice. Federal and State law, as well as member benefit contract language, including definitions and specific contract provisions/exclusions, take precedence over clinical guidelines and must be considered first when determining eligibility for coverage. All final determinations on coverage and payment are the responsibility of the health plan. Nothing contained within this document can be interpreted to mean otherwise. Medical information is constantly evolving, and HealthHelp reserves the right to review and update these clinical guidelines periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from HealthHelp.
    [Show full text]